Your browser is no longer supported. Please, upgrade your browser.
Settings
KOD Kodiak Sciences Inc. daily Stock Chart
KOD [NASD]
Kodiak Sciences Inc.
Index- P/E- EPS (ttm)-1.20 Insider Own20.07% Shs Outstand34.62M Perf Week11.01%
Market Cap576.08M Forward P/E- EPS next Y-1.62 Insider Trans- Shs Float27.83M Perf Month37.86%
Income-44.50M PEG- EPS next Q-0.33 Inst Own54.50% Short Float1.96% Perf Quarter38.67%
Sales- P/S- EPS this Y-42.10% Inst Trans19.79% Short Ratio2.92 Perf Half Y152.12%
Book/sh1.88 P/B8.85 EPS next Y-27.60% ROA-64.80% Target Price20.83 Perf Year-
Cash/sh1.97 P/C8.46 EPS next 5Y12.40% ROE-124.30% 52W Range5.65 - 18.07 Perf YTD134.37%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-7.91% Beta-
Dividend %- Quick Ratio11.30 Sales past 5Y- Gross Margin- 52W Low194.51% ATR1.04
Employees34 Current Ratio11.30 Sales Q/Q- Oper. Margin- RSI (14)69.36 Volatility7.74% 8.22%
OptionableNo Debt/Eq0.00 EPS Q/Q-3.30% Profit Margin- Rel Volume2.87 Prev Close16.66
ShortableYes LT Debt/Eq0.00 EarningsAug 21 BMO Payout- Avg Volume187.36K Price16.64
Recom2.00 SMA2027.81% SMA5030.42% SMA20076.57% Volume538,519 Change-0.12%
Feb-20-19Initiated Chardan Capital Markets Buy $22.50
Oct-29-18Initiated Morgan Stanley Overweight $20
Oct-29-18Initiated BofA/Merrill Buy $14
Oct-29-18Initiated Barclays Overweight $20
Sep-15-19 06:08AM  Kodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting PR Newswire
Sep-12-19 06:00AM  Kodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for wet AMD at The Retina Society Annual Meeting PR Newswire
Sep-06-19 06:00AM  Kodiak Sciences to Present at the Morgan Stanley Global Healthcare Conference PR Newswire
Sep-04-19 06:30PM  Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting PR Newswire
Aug-23-19 11:36AM  Kodiak Sciences Inc. (NASDAQ:KOD) Insiders Increased Their Holdings Simply Wall St.
Aug-14-19 05:30AM  Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlights PR Newswire -9.93%
Aug-08-19 06:00AM  Kodiak Sciences to Present at Wedbush PacGrow Healthcare Conference PR Newswire
Jul-27-19 12:47PM  Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the American Society of Retina Specialists 2019 Annual Meeting PR Newswire
Jul-24-19 07:00AM  Kodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting PR Newswire
Jul-17-19 10:09AM  Kodiak Sciences' Shares March Higher, Can It Continue? Zacks
Jun-17-19 09:56AM  Kodiak Sciences Inc. (KOD) Shares March Higher, Can It Continue? Zacks
May-30-19 07:27PM  Kodiak Sciences to Present at the Jefferies 2019 Healthcare Conference PR Newswire
May-25-19 10:26AM  How Much Of Kodiak Sciences Inc. (NASDAQ:KOD) Do Insiders Own? Simply Wall St.
May-24-19 09:46AM  Kodiak Sciences Inc. (KOD) Shares March Higher, Can It Continue? Zacks
May-15-19 06:00AM  Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights PR Newswire
May-09-19 07:00AM  Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference 2019 PR Newswire
Apr-25-19 04:05PM  Kodiak Sciences Announces Presentations at ARVO 2019 Annual Meeting PR Newswire
Mar-28-19 06:00AM  Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights PR Newswire
Mar-07-19 06:00AM  Kodiak Sciences to Present at the Barclays Global Healthcare Conference PR Newswire -7.44%
Mar-01-19 10:28AM  The Zacks Analyst Blog Highlights: Microsoft, Kodiak Sciences, General Motors and Procter & Gamble Zacks
Feb-28-19 08:15AM  Wall Street Takes Notice of These 4 Stocks - Should You? Zacks
Feb-27-19 11:00AM  The Smartest People on Wall Street Are Buying These 3 Stocks -- Should You Follow? Motley Fool
Feb-08-19 07:00AM  Kodiak Sciences Announces Upcoming Presentation of KSI-301 12-Week Phase 1a Study Data at Angiogenesis, Exudation, and Degeneration 2019 Meeting PR Newswire
Jan-18-19 10:35AM  Have Insiders Been Buying Kodiak Sciences Inc. (NASDAQ:KOD) Shares? Simply Wall St.
Dec-24-18 08:00AM  Kodiak Sciences Added to Russell 2000®, 3000® and Microcap® Indexes PR Newswire +20.13%
Dec-21-18 06:00AM  Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate PR Newswire -6.29%
Dec-05-18 10:35AM  This year's Bay Area IPO batch remains up 44% despite market turbulence American City Business Journals
Nov-16-18 06:00AM  Kodiak Sciences Announces Third Quarter 2018 Financial Results and Recent Business Highlights PR Newswire +9.89%
Oct-31-18 03:34PM  Strong IPO pace continued in October but some cracks are showing American City Business Journals
Oct-26-18 03:05PM  Here are 10 Bay Area accelerators ranked as best in the U.S. American City Business Journals
Oct-10-18 07:00AM  Kodiak Sciences Inc. Announces Closing of Initial Public Offering PR Newswire
Oct-04-18 11:35AM  Kodiak Sciences' stock trades little changed in its debut, after the IPO prices well below the expected range MarketWatch
06:42AM  Kodiak Sciences IPO prices well below expected range MarketWatch
Oct-03-18 10:59PM  Kodiak Sciences Inc. Announces Pricing of Initial Public Offering PR Newswire
Sep-30-18 09:41AM  IPO Outlook For The Week: Diagnostics, Data Miners And Freelance Facilitators Benzinga
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.